CRISPR’s cardio catch-all drives a biotech’s broad potential

3 weeks ago

Add Comment

by David Miller

945 Views

Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

You may also like

About the author

David Miller

Leave a Comment X

Don`t Leave Yet!